Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

PMID: 32140889
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2020
Reference: Invest New Drugs. 2020 Oct;38(5):1570-1579. doi: 10.1007/s10637-020-00910-9. Epub 2020 Mar 5.
Impact factor: 3.525
Publication type: Paper in international publication
Authors: Rodon, Jordi, Capper, David, Guba, Susan C, Wang, Shuaicheng, Wick, Antje, Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana et al.
DOI: 10.1007/s10637-020-00910-9

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

PMID: 32140889
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2020
Reference: Invest New Drugs. 2020 Oct;38(5):1570-1579. doi: 10.1007/s10637-020-00910-9. Epub 2020 Mar 5.
Impact factor:
Publication type: Paper in international publication
Authors: Burkholder, Tiana; Capper, David; Cleverly, Ann Louise; Desjardins, Annick; Estrem, Shawn T; Forsyth, Peter; Guba, Susan C; Gueorguieva, Ivelina; Lahn, Michael M; Rodon, Jordi et al.
DOI: 10.1007/s10637-020-00910-9

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

PMID: 33138866
Journal: BREAST CANCER RESEARCH
Year: 2020
Reference: Breast Cancer Res. 2020 Nov 2;22(1):120. doi: 10.1186/s13058-020-01354-y.
Impact factor: 4.988
Publication type: Paper in international publication
Authors: Villagrasa, Patricia, Li, Yisheng, Savoie, Jennifer, Xu, Zhan, Arteaga, Carlos L, Krop, Ian E, Solit, David B, Mills, Gordon B, Cantley, Lewis C, Winer, Eric P et al.
DOI: 10.1186/s13058-020-01354-y

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

PMID: 33138866
Journal: BREAST CANCER RESEARCH
Year: 2020
Reference: Breast Cancer Res. 2020 Nov 2;22(1):120. doi: 10.1186/s13058-020-01354-y.
Impact factor:
Publication type: Paper in international publication
Authors: Arteaga, Carlos L; Barroso-Sousa, Romualdo; Bermejo, Begona; Cantley, Lewis C; Celiz, Pamela; Ciruelos, Eva; Garrido-Castro, Ana C; Gavila, Joaquin; Guo, Hao; Krop, Ian E et al.
DOI: 10.1186/s13058-020-01354-y

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

PMID: 32661186
Journal: ESMO Open
Year: 2020
Reference: ESMO Open. 2020 Jul;5(4). pii: esmoopen-2020-000673. doi: 10.1136/esmoopen-2020-000673.
Impact factor: 5.329
Publication type: Paper in international publication
Authors: Wen, Patrick Yung, Rodon, Jordi A, Mason, Warren, Beck, Joseph T, DeGroot, John, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Rosenthal, Mark et al.
DOI: 10.1136/esmoopen-2020-000673

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

PMID: 32661186
Journal: ESMO Open
Year: 2020
Reference: ESMO Open. 2020 Jul;5(4). pii: esmoopen-2020-000673. doi: 10.1136/esmoopen-2020-000673.
Impact factor:
Publication type: Paper in international publication
Authors: Beck, Joseph T; DeGroot, John; Donnet, Valerie; El-Hashimy, Mona; Mason, Warren; Mills, David; Rodon, Jordi A; Rosenthal, Mark; Wen, Patrick Yung et al.
DOI: 10.1136/esmoopen-2020-000673

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

PMID: 31778267
Journal: CANCER SCIENCE
Year: 2020
Reference: Cancer Sci. 2020 Feb;111(2):536-547. doi: 10.1111/cas.14254. Epub 2019 Dec 30.
Impact factor: 4.966
Publication type: Paper in international publication
Authors: Bang, Yung-Jue, Su, Wu-Chou, Schuler, Martin, Nam, Do-Hyun, Lim, Wan Teck, Bauer, Todd M, Azaro, Analia, Poon, Ronnie Tung Ping, Hong, David, Lin, Chia-Chi et al.
DOI: 10.1111/cas.14254

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

PMID: 31778267
Journal: CANCER SCIENCE
Year: 2020
Reference: Cancer Sci. 2020 Feb;111(2):536-547. doi: 10.1111/cas.14254. Epub 2019 Dec 30.
Impact factor:
Publication type: Paper in international publication
Authors: Akimov, Mikhail; Azaro, Analia; Bang, Yung-Jue; Bauer, Todd M; Ghebremariam, Samson; Giovannini, Monica; Hong, David; Lim, Wan Teck; Lin, Chia-Chi; Ma, Brigette et al.
DOI: 10.1111/cas.14254

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.

PMID: 32240793
Journal: ANNALS OF ONCOLOGY
Year: 2020
Reference: Ann Oncol. 2020 Jun;31(6):780-788. doi: 10.1016/j.annonc.2020.03.294. Epub 2020 Mar 30.
Impact factor:
Publication type: Paper in international publication
Authors: Arias, M; Aronchik, I; Brana, I; De Alvaro, J; Di Martino, J; Doger, B; Ferrero, O; Filvaroff, E H; Hanna, B; Hernandez-Guerrero, T et al.
DOI: 10.1016/j.annonc.2020.03.294

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma.

PMID: 32327472
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Jul 15;26(14):3546-3556. doi: 10.1158/1078-0432.CCR-19-3239. Epub 2020 Apr 23.
Impact factor: 10.107
Publication type: Paper in international publication
Authors: Gordon, Leo I, Kaplan, Jason B, Popat, Rakesh, Burris, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, Ian et al.
DOI: 10.1158/1078-0432.CCR-19-3239

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma.

PMID: 32327472
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Jul 15;26(14):3546-3556. doi: 10.1158/1078-0432.CCR-19-3239. Epub 2020 Apr 23.
Impact factor:
Publication type: Paper in international publication
Authors: Bosch, Francesc; Burris, Howard A; Carpio, Cecilia; Chau, Ian; El-Sharkawi, Dima; Ferrari, Silvia; Gordon, Leo I; Gritti, Giuseppe; Iyer, Swami; Kaplan, Jason B et al.
DOI: 10.1158/1078-0432.CCR-19-3239

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

PMID: 31540980
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20.
Impact factor: 10.107
Publication type: Paper in international publication
Authors: Gerber, David E, Infante, Jeffrey R, Gordon, Michael S, Goldberg, Sarah B, Burris, Howard A, Martin, Miguel, Felip, Enriqueta, Martinez Garcia, Maria, Schiller, Joan H, Spigel, David R et al.
DOI: 10.1158/1078-0432.CCR-18-3965

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

PMID: 31540980
Journal: CLINICAL CANCER RESEARCH
Year: 2020
Reference: Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20.
Impact factor:
Publication type: Paper in international publication
Authors: Burris, Howard A; Choi, Younjeong; Cordova, Julie; Dere, Randall C; Felip, Enriqueta; Gerber, David E; Goldberg, Sarah B; Gordon, Michael S; Humke, Eric W; Infante, Jeffrey R et al.
DOI: 10.1158/1078-0432.CCR-18-3965

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

PMID: 31395751
Journal: ONCOLOGIST
Year: 2020
Reference: Oncologist. 2020 Jan;25(1):e160-e169. doi: 10.1634/theoncologist.2019-0297. Epub 2019 Aug 8.
Impact factor: 5.025
Publication type: Paper in international publication
Authors: Rodon, Jordi, Janku, Filip, Lolkema, Martijn P, Stephenson, Joe J, Bedard, Philippe L, Schuler, Martin, Sessa, Cristiana, LoRusso, Patricia, Thomas, Michael, Maacke, Heiko et al.
DOI: 10.1634/theoncologist.2019-0297

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

PMID: 31395751
Journal: ONCOLOGIST
Year: 2020
Reference: Oncologist. 2020 Jan;25(1):e160-e169. doi: 10.1634/theoncologist.2019-0297. Epub 2019 Aug 8.
Impact factor:
Publication type: Paper in international publication
Authors: Bardia, Aditya; Bedard, Philippe L; Evans, Helen; Gounder, Mrinal; Janku, Filip; Lolkema, Martijn P; LoRusso, Patricia; Maacke, Heiko; Rodon, Jordi; Schuler, Martin et al.
DOI: 10.1634/theoncologist.2019-0297

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.

PMID: 33246428
Journal: BMC CANCER
Year: 2020
Reference: BMC Cancer. 2020 Nov 27;20(1):1164. doi: 10.1186/s12885-020-07661-z.
Impact factor:
Publication type: Paper in international publication
Authors: Alonso-Orduna, Vicente; Aranda, Enrique; Biondo, Sebastiano; Capdevila, Jaume; Escudero, Pilar; Gallego, Javier; Garcia-Paredes, Beatriz; Gomez-Espana, Auxiliadora; Gravalos, Cristina; Lopez, Carlos et al.
DOI: 10.1186/s12885-020-07661-z

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

PMID: 32554315
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2020
Reference: Eur J Cancer. 2020 Aug;135:89-97. doi: 10.1016/j.ejca.2020.04.031. Epub 2020 Jun 15.
Impact factor: 7.275
Publication type: Paper in international publication
Authors: Amoroso, Loredana, Castel, Victoria, Bisogno, Gianni, Casanova, Michela, Marquez-Vega, Catalina, Chisholm, Julia C, Doz, Francois, Moreno, Lucas, Ruggiero, Antonio, Gerber, Nicolas U et al.
DOI: 10.1016/j.ejca.2020.04.031

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

PMID: 32554315
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2020
Reference: Eur J Cancer. 2020 Aug;135:89-97. doi: 10.1016/j.ejca.2020.04.031. Epub 2020 Jun 15.
Impact factor:
Publication type: Paper in international publication
Authors: Amoroso, Loredana; Bisogno, Gianni; Casanova, Michela; Castel, Victoria; Chen, Nianhang; Chisholm, Julia C; Doz, Francois; Fagioli, Franca; Gerber, Nicolas U; Hingorani, Pooja et al.
DOI: 10.1016/j.ejca.2020.04.031

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

PMID: 32578279
Journal: EUROPEAN JOURNAL OF CANCER CARE
Year: 2020
Reference: Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23.
Impact factor: 2.161
Publication type: Paper in international publication
Authors: Ciruelos, Eva M, Montano, Alvaro, Rodriguez, Cesar A, Gonzalez-Flores, Encarnacion, Lluch, Ana, Garrigos, Laia, Quiroga, Vanesa, Anton, Antonio, Malon, Diego, Chacon, Jose I et al.
DOI: 10.1111/ecc.13253

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

PMID: 32578279
Journal: EUROPEAN JOURNAL OF CANCER CARE
Year: 2020
Reference: Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23.
Impact factor:
Publication type: Paper in international publication
Authors: Amigo, Yolanda; Anton, Antonio; Carrasco, Eva; Casas, Ana; Casas, Maribel; Chacon, Jose I; Ciruelos, Eva M; Echarri, Maria J; Garrigos, Laia; Gonzalez-Cortijo, Lucia et al.
DOI: 10.1111/ecc.13253

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.

PMID: 33262202
Journal: ESMO Open
Year: 2020
Reference: ESMO Open. 2020 Dec;5(6). pii: esmoopen-2020-001081. doi: 10.1136/esmoopen-2020-001081.
Impact factor:
Publication type: Paper in international publication
Authors: Arkenau, Hendrik-Tobias; Azaro, Analia; Bono, Petri; Curigliano, Giuseppe; Garratt, Chris; Hakulinen, Pasi; Ikonen, Tarja; Italiano, Antoine; Kristeleit, Rebecca S; Lassen, Ulrik et al.
DOI: 10.1136/esmoopen-2020-001081

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

PMID: 31959756
Journal: Nature Communications
Year: 2020
Reference: Nat Commun. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3.
Impact factor: 12.121
Publication type: Paper in international publication
Authors: Braso-Maristany, Fara, Griguolo, Gaia, Pascual, Tomas, Pare, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begona, Oliveira, Mafalda, Morales, Serafin, Martinez, Noelia et al.
DOI: 10.1038/s41467-019-14111-3

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

PMID: 31959756
Journal: Nature Communications
Year: 2020
Reference: Nat Commun. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3.
Impact factor:
Publication type: Paper in international publication
Authors: Adamo, Barbara; Alarcon, Jesus; Bermejo, Begona; Braso-Maristany, Fara; Chic, Nuria; Ciruelos, Eva; Cortes, Javier; Galvan, Patricia; Garau, Isabel; Gomis, Roger R et al.
DOI: 10.1038/s41467-019-14111-3

Phenotyping occupational asthma caused by acrylates in a multicentre cohort study.

PMID: 31678289
Journal: Journal of Allergy and Clinical Immunology-In Practice
Year: 2020
Reference: J Allergy Clin Immunol Pract. 2020 Mar;8(3):971-979.e1. doi: 10.1016/j.jaip.2019.10.017. Epub 2019 Oct 31.
Impact factor: 7.574
Publication type: Paper in international publication
Authors: Lindstrom, Irmeli, Sastre, Joaquin, Walusiak-Skorupa, Jolanta, Munoz, Xavier, Talini, Donatella, Klusackova, Pavlina, Moore, Vicky, Merget, Rolf, Svanes, Cecilie, Mason, Paola et al.
DOI: 10.1016/j.jaip.2019.10.017

Publications

Publications searcher

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma.

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma.

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Phenotyping occupational asthma caused by acrylates in a multicentre cohort study.

Patronage:

Collaborating:

Accreditations: